Insider information
23:20 Finnish time / 22:20 Swedish time
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO
With reference to the new share issue announced on
Nanoform expects to receive gross proceeds of approximately
In the Placing, the Company will issue a total of 5,633,803 Shares in a directed share issue. The Shares represent approximately 8.5 per cent of the issued shares in Nanoform prior to the Placing and approximately 7.8 per cent of the issued shares in Nanoform following the Placing. The total number of issued shares in the Company after the Placing will be 72,234,246.
The subscription price of the Shares is
The Placing was carried out based on offers received in an accelerated bookbuilding and based on the authorisations given to the board of directors by the Company's annual general meeting of
Subject to the completion of the Placing, the Shares (ISIN code FI4000330972) will be registered with the trade register maintained by the Finnish Patent and Registration Office on or about
The Company intends to announce updated mid-term business targets for 2025 in connection with its Capital Markets Day on
The CEO of Nanoform, Prof. Edward Hæggström comments: "We are pleased to see strong demand from new and existing Nordic and International investors. With the raised funds we will accelerate Nanoform's growth strategy, including the biologics technology launched in November, 2020."
Board of directors
The information in the company release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on
For further information, please contact:
Albert Hæggström, CFO
albert.haeggstrom@nanoform.com / +358 29 370 0150
For investor relations queries, please contact:
hvh@nanoform.com / +46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
Forward-Looking Statements
This company release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this company release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this company release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines and competition from other companies. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this company release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Important notice
The distribution of this release may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restrictions. The information contained herein is not for publication or distribution, directly or indirectly, in or into
This announcement and this offering are only addressed to and directed at persons in member states of the European Economic Area (each a "Relevant State") who are "
This announcement does not constitute an offer of the securities to the public in the
This release does not constitute an offer for sale of securities in
https://news.cision.com/nanoform/r/nanoform-finland-plc-successfully-completes-new-share-issue-raising-eur-40-million,c3303499
https://mb.cision.com/Main/18905/3303499/1384632.pdf
(c) 2021 Cision. All rights reserved., source